Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib with Obinutuzumab or Venetoclax in Treatment-Naive CLL
NCT05336812Phase 2Recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Sep 2022
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1), venetoclax, obinutuzumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Sep 2022; status: recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)venetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05336812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05336812.